LivaNova
LivaNova (London) entered the race to commercialize the transcatheter mitral valve repair by purchasing the remaining stake in Caisson Interventional in May 2017. At the time, Caisson was developing a transcatheter mitral valve replacement that was designed to be delivered across the septum of the heart through the femoral vein and could be repositioned or withdrawn before final deployment.